UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
April 21, 2009 (April 17, 2009)
Date of Report (Date of earliest event reported)
ENOX BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
Nevada
(State or other jurisdiction of incorporation or organization)
Commission File No. 000-53486
26-0477124
(I.R.S. Employer Identification Number)
3849 West 13th Avenue
Vancouver, BC V6R 2S9
Canada
(Address of principal executive offices)
(604) 637-9744
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN
OFFICERS.
On April 17, 2009, the Board of Directors of Enox Biopharma, Inc. ("Enox," or
the "Company") appointed Dr. Chris Miller, Ph.D., as a director, effective as of
April 17, 2009, to serve until standing for election at the next annual meeting
of the Company's stockholders and until his successor is duly elected and
qualified, or until his earlier resignation or removal. No arrangements or
understandings exist between Mr. Miller and any other person pursuant to which
he was appointed as a director.
Dr. Miller, 51, is a Clinical Assistant Professor in the Faculty of Medicine,
Respiratory Division, at the University of British Columbia, Canada. Dr. Miller
has specialized his research in nitric oxide technology and therapeutic
research. From 1998 to 2007, Dr. Miller served as the CEO of Pulmonox Medical
Inc., a leading-edge biotech company based in Alberta, Canada ("PMI"). PMI is
the successor corporation to Pulmonox Research and Development Corporation, a
company that researched and developed nitric oxide gas as a platform technology
which Dr. Miller founded in 1993. Dr. Miller is also currently a consultant and
sole owner of NRD Solutions, Inc. ("NRD"), a Canadian company which currently
serves a consultant to Enox. Pursuant to the Company's Consulting Agreement with
NRD, NRD evaluates the Company's tympanostomy tube devices, provides opinions on
the Company's devices and technologies and speaks on the Company's behalf to
potential investors, collaborators and partners. NRD receives a fee of $12,000
for a twelve-month period which commenced on September 1, 2008. Dr. Miller is a
principal, owner and founder of Novipan, Inc., a nitric technology development
company. In addition, Dr. Miller is currently a principal, owner and founder of
Nitric Solutions, Inc., a nitric oxide gas manufacturer for human and veterinary
uses. He also continues to consult for biopharmaceutical companies dedicated to
the development of nitric oxide therapies and technologies in the areas of
immunology, cancer and infectious diseases.
From 2007 to 2009, Dr. Miller was a Research Associate in the Division of
Infectious Diseases at the University of British Columbia, where he continued to
develop nitric oxide therapies in the areas of wound healing, leishmaniasis and
tinea pedis. Dr. Miller received a doctorate (2004) in experimental medicine,
pulmonary medicine and infectious diseases from the University of British
Columbia, a B.A. degree (1991) in Management of Health Services from Ottawa
University in Kansas, and an Associate Degree (1982) in Respiratory Therapy from
Northern Alberta Institute of Technology in Edmonton, Canada. His thesis
research evaluated the use of gaseous nitric oxide (gNO) as antibacterial agent
for respiratory tract infections and surface wound infections. Dr. Miller has
authored over 20 papers in peer review publications and has six issued patents
with 14 pending. In 2004, he received the prestigious Jimmy Schultz Award for
his "dedication to improving patient care through research and innovative use of
respiratory care technology."
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ENOX BIOPHARMA, INC.
Date: April 21, 2009 By: /s/ Prof. Yossef Av-Gay
---------------------------------------
Prof. Yossef Av-Gay
President and Chief Executive Officer
3